retatrutide clinical trial done! Now onto Zep! : r/Zepbound A New Obesity Drug Delivered

Plaintiffs pursuing GLP-1 vision loss lawsuits allege that manufacturers failed to adequately warn patients and prescribing physicians about reports of NAION and other potentially irreversible eye complications associated with semaglutide medications

Garca-Cceres C, Quarta C, Varela L, Gao Y, Gruber T, Legutko B, et al

Submission of the drug for FDA approval for weight loss is expected after completion of a second phase 3 trial, SURMOUNT-2, in spring 2023

The medication reduced 17-24% of body weight with consistent use over 48 weeks

As demonstrated in this study, short-acting GLP-1RAs, such as lixisenatide, were associated with a significantly higher risk of nausea and vomiting compared to long-acting and ultra-long-acting GLP-1RAs, such as dulaglutide and semaglutide

The adverse events that occurred with the 7 GLP-1RAs were largely reversible, scoring 0.5 point